In the pilot clinical study we investigated the effect of systemic [intravenous] transplantation of cardiomyoblasts which have been received by action of specific inducer of cardiomyogenic differentiations — 5-azacytidine on cultured from autologous bone marrow mesenchymal stem cells at 46 patients with the chronic heart failure received also the standard course of medicamentous therapy. The technique of cardiomyoblasts and mesenchymal stem cells production has been licensed by Federal Agency on Supervision in the Field of Public Health Services [license FA-2006/206 from August, 11th, 2006]. It has been shown that the cell therapy with use of autologous cardiomyoblasts has minimal invasiveness, it does not cause any complications [allergic reactions, hazardous to health arrhythmia, embolism, heavy frustration of haemodynamics, etc.] and also does not lead to level of health after cells transplantation. In the first 3—6 months after systemic transplantation of progenitor cells for cardiomyocytes we developed at patients advanced heart contractive activity and increased myocardium perfusion that was clinically shown in reduction of the heart failure level with further long stable health compensation [till 1—2 years of monitoring].